Paper Details

  1. Home
  2. Paper Details

The addition of salmeterol 50 microg bid to anticholinergic treatment in patients with COPD: a randomized, placebo controlled trial. Chronic obstructive pulmonary disease.

Author: , ArvidssonPeter, ChapmanKenneth R, ChuchalinA G, DhillonD P, FaurschouPeter, GoldsteinRoger S, KuipersA F

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This double-blind, randomized, parallel-group study compared the effect of adding salmeterol (50 microg bid) or placebo to concurrent anticholinergic therapy on symptom scores, quality of life, prebronchodilator lung function, and exacerbations in 408 patients with moderately severe chronic obstructive pulmonary disease (COPD). Salmeterol has a beneficial effect when added to existing anticholinergic therapy in patients with COPD. The regular use of salmeterol for six months was not associated with worsening of the underlying airflow obstruction.
Paper Details　
Original Abstract of the Article :
BACKGROUND: In the past, the role of long-acting beta(2-) agonists in chronic obstructive pulmonary disease (COPD) relative to other agents has been unclear. OBJECTIVES: To compare the effect of adding salmeterol (50 microg bid) or placebo to concurrent anticholinergic therapy on symptom scores, qu...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1155/2002/493296

データ提供：米国国立医学図書館（NLM）

Salmeterol: A Potential Booster for COPD Treatment

Chronic obstructive pulmonary disease (COPD), a lung disease that makes breathing difficult, is a significant health concern. This study examines the potential benefits of adding salmeterol, a long-acting beta2-agonist, to anticholinergic therapy in patients with COPD. The study, a double-blind, randomized controlled trial, aimed to compare the effects of adding salmeterol or placebo to the existing treatment regimen.

Salmeterol: A Possible Improvement to COPD Treatment

The study found that adding salmeterol to anticholinergic therapy led to significant improvements in lung function, measured by forced expiratory volume in 1 second (FEV1). The addition of salmeterol resulted in a greater increase in FEV1 compared to placebo, particularly in the initial weeks of treatment. The study also observed a trend towards fewer exacerbations and an improved quality of life in patients who received salmeterol.

Breathing Easier: Understanding COPD Treatment Options

This study highlights the potential benefits of adding salmeterol to anticholinergic therapy for COPD. The findings suggest that salmeterol can improve lung function, reduce the frequency of exacerbations, and enhance quality of life. However, it's important to note that salmeterol did not significantly improve symptom scores or reduce the need for rescue bronchodilators.

Dr.Camel's Conclusion

This study, like a refreshing breeze in the desert, offers hope for individuals with COPD. It suggests that adding salmeterol to existing treatment may help improve lung function and quality of life. It's like adding a boost of energy to your lungs, helping you navigate the challenges of COPD more easily.

Date :
  1. Date Completed 2002-10-28
  2. Date Revised 2018-05-25
Further Info :

Pubmed ID

12068339

DOI: Digital Object Identifier

10.1155/2002/493296

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.